DE69815008D1 - Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel - Google Patents

Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel

Info

Publication number
DE69815008D1
DE69815008D1 DE69815008T DE69815008T DE69815008D1 DE 69815008 D1 DE69815008 D1 DE 69815008D1 DE 69815008 T DE69815008 T DE 69815008T DE 69815008 T DE69815008 T DE 69815008T DE 69815008 D1 DE69815008 D1 DE 69815008D1
Authority
DE
Germany
Prior art keywords
alpha
acid derivatives
phenylpropionic acid
medicaments containing
substituted phenylpropionic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69815008T
Other languages
English (en)
Other versions
DE69815008T2 (de
Inventor
Yoshihiro Nagao
Fujiko Konno
Jiro Kotake
Fumio Ishii
Haruyoshi Honda
Susumu Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SSP Co Ltd
Original Assignee
SSP Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SSP Co Ltd filed Critical SSP Co Ltd
Application granted granted Critical
Publication of DE69815008D1 publication Critical patent/DE69815008D1/de
Publication of DE69815008T2 publication Critical patent/DE69815008T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D237/00Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30Phthalazines
    • C07D237/32Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36Oxygen or sulfur atoms
    • C07D207/382-Pyrrolones
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36Radicals substituted by singly-bound nitrogen atoms
    • C07D213/42Radicals substituted by singly-bound nitrogen atoms having hetero atoms attached to the substituent nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/78Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
    • C07D239/80Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/86Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72Quinazolines; Hydrogenated quinazolines
    • C07D239/95Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96Two oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D243/00Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/08Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D265/00Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/041,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/121,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems
    • C07D265/141,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D265/201,3-Oxazines; Hydrogenated 1,3-oxazines condensed with carbocyclic rings or ring systems condensed with one six-membered ring with hetero atoms directly attached in position 4
    • C07D265/22Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D473/00Heterocyclic compounds containing purine ring systems
    • C07D473/02Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE69815008T 1997-09-19 1998-09-10 Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel Expired - Fee Related DE69815008T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP25502597 1997-09-19
JP25502597 1997-09-19

Publications (2)

Publication Number Publication Date
DE69815008D1 true DE69815008D1 (de) 2003-07-03
DE69815008T2 DE69815008T2 (de) 2004-04-01

Family

ID=17273148

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69815008T Expired - Fee Related DE69815008T2 (de) 1997-09-19 1998-09-10 Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel

Country Status (7)

Country Link
EP (1) EP0903343B1 (de)
KR (1) KR19990029839A (de)
CN (1) CN1215051A (de)
CA (1) CA2247772A1 (de)
DE (1) DE69815008T2 (de)
ES (1) ES2200248T3 (de)
TW (1) TW474922B (de)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6313113B1 (en) * 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
WO1999016758A1 (en) * 1997-10-27 1999-04-08 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6265401B1 (en) * 1997-10-27 2001-07-24 Reddy-Cheminor, Inc. Bicyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
GB2364304B (en) 1997-10-27 2003-04-23 Reddy Research Foundation Novel tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
US6444816B1 (en) 1997-10-27 2002-09-03 Dr. Reddy's Research Foundation Fused 7-oxo-pyrimidinyl compounds, preparation, composition and use thereof
CA2307068C (en) 1997-10-27 2007-04-10 Dr. Reddy's Research Foundation Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP1051403A1 (de) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Alkansaüren und deren verwendung in heilmittel, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
WO2000063189A1 (en) * 1999-04-16 2000-10-26 Novo Nordisk A/S Crystalline r- guanidines, arginine or (l) -arginine (2s) -2- ethoxy -3-{4- [2-(10h -phenoxazin -10-yl)ethoxy]phenyl}propanoate
BR0009864A (pt) * 1999-04-20 2002-01-08 Novo Nordisk As Composto, composição farmacêutica, métodos para o tratamento de doenças, para o tratamento e/ou prevenção de condições mediadas pelos receptores nucleares e para o tratamento e/ou prevenção de diabete e/ou obesidade, e, uso de um composto
US6274608B1 (en) 1999-04-20 2001-08-14 Novo Nordisk A/S Compounds, their preparation and use
US6972294B1 (en) 1999-04-20 2005-12-06 Novo Nordisk, A/S Compounds, their preparation and use
JP2002542246A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
US7414128B2 (en) 1999-04-20 2008-08-19 Dr. Reddy's Laboratories, Limited Crystalline R-guanidines, Arginine or (L)-Arginine (2S)-2-Ethoxy-3-{4-[2-(10H -phenoxazin-10-yl)ethoxy]phenyl}propanoate
JP2002542237A (ja) * 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
US6369055B1 (en) 1999-04-20 2002-04-09 Novo Nordisk A/S Compounds, their preparation and use
BRPI0108024B8 (pt) * 2000-01-19 2021-05-25 Cadila Healthcare Ltd composto, processo para a preparação de um composto, composição farmacêutica, uso do composto, novo intermediário e processo para a preparação de um novo intermediário
CA2395298A1 (en) * 2000-01-28 2001-08-02 Novo Nordisk A/S Propionic acid derivatives and their use in the treatment of diabetes and obesity
US6555577B1 (en) 2000-01-28 2003-04-29 Novo Nordisk A/S Compounds, their preparation and use
US6569901B2 (en) 2000-01-28 2003-05-27 Novo Nordisk A/S Alkynyl-substituted propionic acid derivatives, their preparation and use
WO2002062799A1 (en) * 2001-02-05 2002-08-15 Dr. Reddy's Laboratories Ltd. Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
IL158589A0 (en) 2001-05-15 2004-05-12 Hoffmann La Roche Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
PL368051A1 (en) 2001-06-07 2005-03-21 Eli Lilly And Company Modulators of peroxisome proliferator activated receptors
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
JP2005518408A (ja) 2001-12-29 2005-06-23 ノボ ノルディスク アクティーゼルスカブ 異常脂肪血症を治療するための、glp−1化合物と他の薬物との組み合わせ使用
KR100621294B1 (ko) 2002-07-03 2006-09-06 에프. 호프만-라 로슈 아게 옥사졸 유도체 및 이의 인슐린 증감제로서의 용도
EP1537091B1 (de) 2002-08-30 2010-10-06 F. Hoffmann-La Roche AG Neue 2-arylthiazolverbindungen als ppar-alpha und -gamma agonisten
RU2296759C2 (ru) 2002-09-12 2007-04-10 Ф.Хоффманн-Ля Рош Аг N-замещенные 1н-индол-5-пропионовые кислоты, фармацевтическая композиция, содержащая эти соединения, и их применение (варианты)
MXPA05005445A (es) 2002-11-25 2005-08-26 Hoffmann La Roche Derivados de indolilo.
WO2005042712A2 (en) * 2003-10-28 2005-05-12 Reddy Us Therapeutics, Inc. Heterocyclic compounds and methods of making and using thereof
WO2007033002A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
US9114138B2 (en) 2007-09-14 2015-08-25 Janssen Pharmaceuticals, Inc. 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones
WO2010025890A1 (en) 2008-09-02 2010-03-11 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009319387B2 (en) 2008-11-28 2012-05-10 Addex Pharma S.A. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
JP5634506B2 (ja) 2009-05-12 2014-12-03 ジャンセン ファーマシューティカルズ, インコーポレイテッド 1,2,3−トリアゾロ[4,3−a]ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用
CA2760259C (en) 2009-05-12 2018-05-01 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JP5852666B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
ES2552455T3 (es) 2010-11-08 2015-11-30 Janssen Pharmaceuticals, Inc. Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2
JP5852665B2 (ja) 2010-11-08 2016-02-03 ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
CN109400502A (zh) * 2013-07-22 2019-03-01 新陈代谢解决方案开发公司 用于治疗代谢疾病的ppar-节制性化合物
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
WO2015110435A1 (en) 2014-01-21 2015-07-30 Janssen Pharmaceutica Nv Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use
LT3096790T (lt) 2014-01-21 2019-10-10 Janssen Pharmaceutica, N.V. Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
JPH08325264A (ja) * 1995-05-31 1996-12-10 Sumitomo Metal Ind Ltd 新規2−芳香環置換−3−フェニルプロピオン酸またはアクリル酸誘導体
DE19546918A1 (de) * 1995-12-15 1997-06-19 Bayer Ag Bicyclische Heterocyclen
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds

Also Published As

Publication number Publication date
DE69815008T2 (de) 2004-04-01
KR19990029839A (ko) 1999-04-26
CA2247772A1 (en) 1999-03-19
EP0903343B1 (de) 2003-05-28
TW474922B (en) 2002-02-01
ES2200248T3 (es) 2004-03-01
EP0903343A1 (de) 1999-03-24
CN1215051A (zh) 1999-04-28

Similar Documents

Publication Publication Date Title
DE69815008D1 (de) Alfa-substituierte Phenylpropionsäurederivate und diese enthaltende Arzneimittel
ATE243516T1 (de) Amoxicillin und clavulanat enthaltende arzneizubereitungen
DE69328492D1 (de) Fettsäure-derivate und diese enthaltende pharmazeutische präparationen
FI972292A0 (fi) Administrering av diabetes
ATE187063T1 (de) Arzneimittel
DE122010000011I1 (de) Flüssige gonadotropinhaltige Arzneimittel
DE69429821T2 (de) Farnesyl-derivate und diese enthaltende arzneimittel
ATE288419T1 (de) Alpha-aryl-n-alkylnitrone sowie diese enthaltende pharmazeutische zubereitungen
DE59813619D1 (de) Ascorbinsäurederivate enthaltende kosmetische und pharmazeutische Zubereitungen
DE69732649D1 (de) Heteroarylsulfonamidderivate und diese enthaltende pharmazeutische zubereitungen
ATE297935T1 (de) 2-(iminomethyl)aminophenyl-derivate, deren herstellung, verwendung als medikamente und diese enthaltende pharmazeutische zubereitungen
BR9610983A (pt) Formas estáveis de administração farmacêuticas contendo paratormônio
NO305903B1 (no) Benzonitriler og benzofluorider, legemidler bestående av forbindelsene, farmasöytiske preparater inneholdende forbindelsene, samt anvendelse av forbindelsene for fremstilling av farmasöytiske preparater
DE69813602D1 (de) Venlafaxinhaltiges arzneimittel mit verlängerter wirkstoffabgabe
DE4494713T1 (de) Arylsulfonamidderivate und diese Derivate enthaltende Arzneimittel
ATE250570T1 (de) Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
EE04263B1 (et) Farmatseutiline kompositsioon piperidinoalkanoolantihistamiini ja selle derivaatide biosaadavuse suurendamiseks ning allergiliste reaktsioonide raviks patsiendil
DE69718077D1 (de) Arzneimittel bestehend aus Diclofenac
NO20001717D0 (no) Serotonin-inneholdende formulering for oral administrering og anvendelse av samme
ATE310726T1 (de) Pyridin-derivate und diese enthaltende pharmazeutische mittel
DE69907735D1 (de) Melatoninderivate und diese enthaltende pharmazeutische zubereitung
ATE256465T1 (de) Orale arzneimittel zubereitung von piperdinoalkanole in gelöster form
DE60139306D1 (de) N-deacetylthiocolchin-derivate und diese enthaltende arzneimittel
DE69725166D1 (de) Substituierte benzamidderivate und diese enthaltende pharmazeutische zusammensetzung
DE69622648D1 (de) Benzoxalepin-derivate, deren salze und diese enthaltende arzneimittel

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee